New Cryopreservation Technology of hMSCs: First Preclinical Results Using DMSO-containing Medium
Language English Country Great Britain, England Media print
Document type Journal Article
PubMed
33973985
Knihovny.cz E-resources
- MeSH
- Dimethyl Sulfoxide * pharmacology MeSH
- Clinical Trials as Topic MeSH
- Cryopreservation MeSH
- Cryoprotective Agents pharmacology MeSH
- Humans MeSH
- Mesenchymal Stem Cells * MeSH
- Flow Cytometry MeSH
- Technology MeSH
- Cell Survival MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Dimethyl Sulfoxide * MeSH
- Cryoprotective Agents MeSH
BACKGROUND: Human mesenchymal stem cells (hMSCs) have tremendous potential in regenerative medicine, making it desirable to cryopreserve and bank them to increase their access and availability. OBJECTIVE: This research is part of a clinical trial performed on six patients that aimed to use advanced therapy medicinal products (ATMPs) based on hMSCs in patients undergoing repeated total hip replacement. MATERIALS AND METHODS: To compare the characteristics of fresh and frozen hMSCs, we used the trypan blue exclusion test (cell viability), flow cytometry (cell viability and phenotyping), sterility determinations and the clonogenic assay of cell proliferation. RESULTS: Cryopreserved hMSCs showed good quality parameters after thawing in comparison with fresh hMSCs in suspension. When using a medium containing dimethyl sulfoxide (DMSO), the viability was higher than 90% in all cases. The cell purity determined by flow cytometry was also acceptable. CONCLUSION: These initial results show that the prepared cryopreserved ATMP exhibited good viability and phenotype characteristics.
Bioinova Ltd Prague Czech Republic
Faculty of Military Medicine of the University of Defence in Hradec Kralove Czech Republic
Tissue Bank University Hospital Hradec Kralove Hradec Kralove Czech Republic
